Absci
NASDAQ: ABSIPortland, US · Founded 2020 · Delaware corporation · 159 employees on LinkedIn · 12 known investors
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch. It develops drug candidates like ABS-201 for conditions including androgenetic alopecia and applies reverse immunology for novel target discovery.
Founders & leadership
Absci was founded in 2020 by Sean McClain.
SM
PB
Phil BarishExecutive
Board
ZJ
Zach JonassonBoard director
DG
Daniel GoldBoard director
BL
Bryan LawlisBoard director
Investors · 12
Das & Co.New York
Oregon Venture FundPortland · $500K – $5M
Phoenix Venture PartnersSan Mateo · $100K – $3M
Tachyon VenturesLos Angeles
Tau VenturesPalo Alto · $500K
Biotechnology Value FundreportedSan Francisco
Casdin CapitalreportedNew Yorkvia Eli Casdin · board
InvusreportedNew York
REDMILEreportedSan Francisco
Also in the syndicate · 3
AdageColumbia ThreadneedleEli Lilly & Company
Funding
SEC filings, press & company announcements$321M disclosed across 6 rounds · 2016–2026
- $100MraisedJun 2026 · 3 sources
Adage, BVF Partners, Columbia Threadneedle, Eli Lilly & Company, Invus, Redmile
Source ↗
▶$125MraisedMar 2021 · 24 investors · BiotechnologyRule 506(b)
▶$125MraisedMar 2021 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andreas PihlDirector
- Gustavo MahlerDirector
- Karen McGinnisDirector
- Ivana Magovcevic-LiebischDirector
- V. Bryan LawlisDirector
- Zach JonassonDirector
- Gregory SchiffmanExecutive Officer
- Sean McClainExecutive Officer, Director
- Eli CasdinDirector
- Amrit NagpalDirector
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$70MraisedMar 2021 · 14 investors · BiotechnologyRule 506(b)
▶$70MraisedMar 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence McClureExecutive Officer
- Zach JonassonDirector
- Eli CasdinDirector
- Andreas PihlDirector
- Amrit NagpalDirector
- Karen McGinnisDirector
- Gustavo MahlerDirector
- Ivana Magovcevic-LiebischDirector
- V. Bryan LawlisDirector
- Gregory SchiffmanExecutive Officer
- Sean McClainExecutive Officer, Director
- Offering amount
- $70M
- Amount sold
- $70M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10.4MraisedDec 2019 · 17 investors · BiotechnologyRule 506(b)
▶$10.4MraisedDec 2019 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean McClainExecutive Officer, Director
- Shelley KlassenExecutive Officer
- Zach JonassonDirector
- Bryan LawlisDirector
- Daniel GoldDirector
- Gustavo MahlerDirector
- Offering amount
- $15M
- Amount sold
- $10.4M
- Minimum investment
- $10K
- Proceeds to insiders
- $1M
- First sale
- Dec 2019
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
▶$12MraisedJun 2018 · 31 investors · BiotechnologyRule 506(b)
▶$12MraisedJun 2018 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phil BarishExecutive Officer, Director
- Daniel GoldDirector
- Gustavo MahlerDirector
- Sean McClainExecutive Officer, Director
- Bryan LawlissDirector
- Zach Zach JonassonDirector
- Shelley KlassenExecutive Officer
- Offering amount
- $15M
- Amount sold
- $12M
- Proceeds to insiders
- $500K
- First sale
- May 2018
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
▶$3.7MraisedApr 2016 · 12 investors · BiotechnologyRule 506(b)
▶$3.7MraisedApr 2016 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Zach JonassonDirector
- Bryan LawlisDirector
- Phil BarishExecutive Officer
- Daniel GoldDirector
- Sean McClainExecutive Officer
- Offering amount
- $6M
- Amount sold
- $3.7M
- Minimum investment
- $10K
- Proceeds to insiders
- $325K
- First sale
- Apr 2016
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Absci went on to found or lead other companies.
Competitors · 5
by search overlap
Seeking Alpha53 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St34 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
StockTwits32 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
TradingView29 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Public29 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Companies competing with Absci for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Absci do?
- Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch. It develops drug candidates like ABS-201 for conditions including androgenetic alopecia and applies reverse immunology for novel target discovery.
- Who founded Absci?
- Absci was founded by Sean McClain in 2020.
- Who are Absci's investors?
- Absci's investors include Das & Co., Oregon Venture Fund, Phoenix Venture Partners, Tachyon Ventures, Tau Ventures, Biotechnology Value Fund, Casdin Capital, Invus and 1 more.
- How much funding has Absci raised?
- Absci has disclosed $321M raised across 6 rounds.
- Where is Absci headquartered?
- Absci is headquartered in Portland, US.